Vical Incorporated (NASDAQ:VICL) Director Robert C. Merton purchased 85,700 shares of Vical stock in a transaction dated Friday, November 10th. The stock was acquired at an average price of $1.75 per share, with a total value of $149,975.00. Following the acquisition, the director now owns 95,451 shares in the company, valued at approximately $167,039.25. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Vical Incorporated (NASDAQ VICL) traded down $0.01 during midday trading on Wednesday, hitting $1.90. 402,800 shares of the company traded hands, compared to its average volume of 172,048. Vical Incorporated has a 1 year low of $1.66 and a 1 year high of $3.70.

Vical (NASDAQ:VICL) last posted its quarterly earnings data on Monday, October 23rd. The biotechnology company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.02). The firm had revenue of $3.24 million for the quarter, compared to the consensus estimate of $3.60 million. Vical had a negative return on equity of 29.06% and a negative net margin of 92.13%. analysts forecast that Vical Incorporated will post -1.07 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Vical Incorporated (VICL) Director Robert C. Merton Purchases 85,700 Shares of Stock” was first posted by Daily Political and is the property of of Daily Political. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/11/15/vical-incorporated-vicl-director-robert-c-merton-purchases-85700-shares-of-stock.html.

Several equities research analysts have recently commented on the stock. ValuEngine lowered shares of Vical from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. HC Wainwright set a $9.00 price target on shares of Vical and gave the company a “buy” rating in a report on Wednesday, August 9th. Ifs Securities restated an “outperform” rating on shares of Vical in a report on Tuesday, August 8th. Finally, Zacks Investment Research lowered shares of Vical from a “hold” rating to a “sell” rating in a report on Thursday, October 26th. Two investment analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $9.00.

A hedge fund recently raised its stake in Vical stock. Renaissance Technologies LLC increased its position in shares of Vical Incorporated (NASDAQ:VICL) by 6.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 416,029 shares of the biotechnology company’s stock after acquiring an additional 23,520 shares during the quarter. Renaissance Technologies LLC’s holdings in Vical were worth $932,000 as of its most recent SEC filing. Institutional investors and hedge funds own 21.39% of the company’s stock.

About Vical

Insider Buying and Selling by Quarter for Vical (NASDAQ:VICL)

Receive News & Ratings for Vical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.